Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F23%3A00081740" target="_blank" >RIV/65269705:_____/23:00081740 - isvavai.cz</a>

Výsledek na webu

<a href="https://www.nature.com/articles/s41409-022-01870-9" target="_blank" >https://www.nature.com/articles/s41409-022-01870-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41409-022-01870-9" target="_blank" >10.1038/s41409-022-01870-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Popis výsledku v původním jazyce

Myelodysplastic syndrome unclassifiable (MDS-U) encompasses an infrequent subtype of MDS, categorised into three entities; MDS-U with 1% blasts (MDS-U-BL), MDS-U with single lineage dysplasia and pancytopenia (MDS-U-SLD-pan), and MDS-U with defining cytogenetic abnormalities (MDS-U-CG). There is a scarcity of evidence in the literature focused on MDS-U and due to lack of robust disease characterisation, despite stringent diagnostic criteria, little is known about the inherent risk profile of MDS-U. Therapeutic decisions in MDS-U are frequently made using &apos;general rules&apos; applied to all MDS cases, yet robust outcome and safety analyses for this specific group of patients are lacking.

Název v anglickém jazyce

Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable - a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

Popis výsledku anglicky

Myelodysplastic syndrome unclassifiable (MDS-U) encompasses an infrequent subtype of MDS, categorised into three entities; MDS-U with 1% blasts (MDS-U-BL), MDS-U with single lineage dysplasia and pancytopenia (MDS-U-SLD-pan), and MDS-U with defining cytogenetic abnormalities (MDS-U-CG). There is a scarcity of evidence in the literature focused on MDS-U and due to lack of robust disease characterisation, despite stringent diagnostic criteria, little is known about the inherent risk profile of MDS-U. Therapeutic decisions in MDS-U are frequently made using &apos;general rules&apos; applied to all MDS cases, yet robust outcome and safety analyses for this specific group of patients are lacking.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30205 - Hematology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Bone Marrow Transplantation

ISSN

0268-3369

e-ISSN

1476-5365

Svazek periodika

58

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

4

Strana od-do

222-225

Kód UT WoS článku

000885404500002

EID výsledku v databázi Scopus

2-s2.0-85142143668